SCHEMBL6084633

SCHEMBL6084633

Cc1ccc2nc(-c3c[nH]nc3-c3ccc(NC(=O)C4CCc5ccccc5C4)cc3)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 2/20 0.46
MAPT P10636 8/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
POLB P06746 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
GHSR Q92847 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
AGPAT2 O15120 1/20 0.42
ROCK1 Q13464 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
ROCK2 O75116 1/20 0.41
TP53 P04637 4/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086026 0.85 CEPT1 (0.47) MAPTSMN1; SMN2NPC1RAB9AGHSR
SCHEMBL6085049 0.82 CETP (0.50) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6085303 0.81 MAPT (0.50) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6670100 0.81 NPC1 (0.47) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6085861 0.80 NPC1 (0.52) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6085641 0.80 NPC1 (0.52) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6086086 0.78 MAPT (0.50) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6086313 0.78 CETP (0.56) CETPMAPTSMN1; SMN2POLBNPC1
SCHEMBL6085642 0.78 MAPT (0.55) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6085323 0.78 MAPT (0.55) MAPTSMN1; SMN2POLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CETP 4875/4885MAPT 801/4885SMN1; SMN2 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.